MyFinsight
Home
Blog
About
Contact
Download
Download image
Net loss
attributable to oncotelic...
-$1,047.365K
(68.30%↑ Y/Y)
Net loss
attributable to...
-$67.004K
(0.24%↑ Y/Y)
Net loss before
non-controlling interests
-$1,114.369K
(66.95%↑ Y/Y)
Total other expense
-$623.396K
(-585.85%↓ Y/Y)
Loss from operations
-$490.973K
(85.03%↑ Y/Y)
Change in fair value of
derivative on debt
-$392.058K
(-441.75%↓ Y/Y)
Interest expense, net
$231.338K
(12.51%↑ Y/Y)
Total operating
expenses
$490.973K
(-85.03%↓ Y/Y)
General and
administrative
$490.547K
(511.07%↑ Y/Y)
Research and development
$0.426K
(-11.25%↓ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
Oncotelic Therapeutics, Inc. (OTLC)
Oncotelic Therapeutics, Inc. (OTLC)